For the quarter ending 2026-03-31, PMN had $57,697,789 increase in cash & cash equivalents over the period.
| Cash Flow | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 |
|---|---|---|---|---|
| Net loss | -8,244,372 | -10,674,088 | -11,580,127 | -17,464,932 |
| Share-based compensation expense | 189,425 | 203,171 | 197,147 | 457,310 |
| Change in fair value of financial instruments | - | 5,592 | - | - |
| Prepaid expenses and other current assets | 531,362 | -2,993,819 | 1,059,605 | -620,912 |
| Accounts payable | -826,591 | -1,668,070 | 1,431,306 | 1,042,716 |
| Accrued liabilities | -2,970,620 | -131,146 | 955,654 | 6,562,946 |
| Net cash used in operating activities | -12,383,520 | -9,281,906 | -10,055,625 | -8,781,048 |
| Purchase of short-term investments | - | 33,753 | - | - |
| Maturity of short-term investment | - | 33,051 | - | - |
| Net cash used in investing activities | - | -702 | - | - |
| Proceeds from issuance of common shares pursuant to 2025 and 2024 atm offering, respectively, net of issuance costs | - | 0 | 708,468 | - |
| Proceeds from issuance of pre-funded warrants from july 22, 2025 registered direct offering, net of issuance costs | - | - | 697,658 | - |
| Proceeds from issuance of pre-funded warrants from july 22, 2025 registered direct offering, net of issuance costs-July222025Exercise Of Discounted Warrants And Pipe Offering | - | 697,658 | - | - |
| Proceeds from issuance of common shares, pre-funded warrants and accompanying common warrants from private placements, net of issuance costs-July222025Exercise Of Discounted Warrants And Pipe Offering | - | 0 | 8,391,027 | - |
| Proceeds from issuance of common shares, pre-funded warrants and accompanying common warrants from private placements, net of issuance costs-July282025Exercise Of Discounted Warrants And Pipe Offering | - | -1 | 11,144,468 | - |
| Proceeds from exercise of pre-funded warrants | - | 0 | 3,050 | - |
| Proceeds from issuance of common shares, pre-funded warrants, and common warrants from january 29, 2026 pipe, net of issuance costs | 70,081,309 | - | - | - |
| Net cash provided by financing activities | 70,081,309 | -1 | 20,944,671 | - |
| Net increase (decrease) in cash | 57,697,789 | -9,282,609 | 10,889,046 | -8,781,048 |
| Cash at beginning of period | 6,116,556 | 15,399,165 | 13,291,167 | - |
| Cash at end of period | 63,814,345 | 6,116,556 | 15,399,165 | - |
ProMIS Neurosciences Inc. (PMN)
ProMIS Neurosciences Inc. (PMN)